Literature DB >> 8204582

Evidence that the nature of amino acid residues in the P3 position directs substrates to distinct catalytic sites of the pituitary multicatalytic proteinase complex (proteasome).

C Cardozo1, A Vinitsky, C Michaud, M Orlowski.   

Abstract

Cleavage of bonds after neutral amino acids by the multicatalytic proteinase complex (MPC) has been recently shown to be catalyzed by at least three distinct components [Orlowski, M., Cardozo, C., & Michaud, C. (1993) Biochemistry 32, 1563-1572]. One component, designated as chymotrypsin-like (ChT-L), cleaves peptide bonds on the carboxyl side of hydrophobic residues and is also active toward peptidyl-arylamide bonds. A second component, designated as branched-chain amino acid preferring (BrAAP), and a third component, designated as small neutral amino acid preferring (SNAAP), cleave preferentially bonds on the carboxyl side of branched-chain amino acids and between small neutral amino acids, respectively. Evidence indicates that the BrAAP component is a major factor responsible for degradation of protein by the MPC. The purpose of the present study was to identify the structural requirements that determine the involvement of these components in cleavage of peptides after different neutral amino acids. A series of substrates was synthesized with the aim of probing the role of residues beyond those flanking the scissile bond in directing substrates to defined catalytic sites. The data indicate that a proline or glycine residue in the P3 position directs the substrate to the catalytic site of the BrAAP component provided that a branched-chain amino acid is present in the P1 position. A proline residue in P3 is also important for involvement of the SNAAP component in substrate degradation. The presence of this residue interferes with substrate binding to the catalytic site of the ChT-L activity, even in the presence of a phenylalanine residue in the P1 position.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8204582     DOI: 10.1021/bi00187a014

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  7 in total

1.  Global analysis of proteasomal substrate specificity using positional-scanning libraries of covalent inhibitors.

Authors:  T Nazif; M Bogyo
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

2.  A mathematical model of protein degradation by the proteasome.

Authors:  Fabio Luciani; Can Keşmir; Michele Mishto; Michal Or-Guil; Rob J de Boer
Journal:  Biophys J       Date:  2005-01-21       Impact factor: 4.033

Review 3.  Antigen processing by proteasomes: insights into the molecular basis of crypticity.

Authors:  H Djaballah
Journal:  Mol Biol Rep       Date:  1997-03       Impact factor: 2.316

4.  The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.

Authors:  G R Tundo; D Sbardella; A M Santoro; A Coletta; F Oddone; G Grasso; D Milardi; P M Lacal; S Marini; R Purrello; G Graziani; M Coletta
Journal:  Pharmacol Ther       Date:  2020-05-19       Impact factor: 12.310

5.  The proteasome 11S regulator subunit REG alpha (PA28 alpha) is a heptamer.

Authors:  S C Johnston; F G Whitby; C Realini; M Rechsteiner; C P Hill
Journal:  Protein Sci       Date:  1997-11       Impact factor: 6.725

6.  Branched-chain-amino-acid-preferring peptidase activity of the lobster multicatalytic proteinase (proteasome) and the degradation of myofibrillar proteins.

Authors:  D L Mykles; M F Haire
Journal:  Biochem J       Date:  1995-02-15       Impact factor: 3.857

7.  Cytotoxic T lymphocyte epitopes of HIV-1 Nef: Generation of multiple definitive major histocompatibility complex class I ligands by proteasomes.

Authors:  M Lucchiari-Hartz; P M van Endert; G Lauvau; R Maier; A Meyerhans; D Mann; K Eichmann; G Niedermann
Journal:  J Exp Med       Date:  2000-01-17       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.